Table 2.

Organ involvement at onset (%).

	EGPA Patients with IVIG, n = 22	EGPA Patients without IVIG, n = 24	p
Asthma	100	100	NS^*
Paranasal sinusitis	100	87	NS^*
Multiple polyneuropathy	100	100	NS^*
Minimum MMT score, mean ± SD	2.6 ± 1.0	3.9 ± 0.8	p < 0.01^†
Pulmonary infiltrates	76.2	81.8	NS^*
Myocardial involvement	78.9	47.8	0.04^*
Gastrointestinal tract	90	58.3	0.02^*
Liver, gall bladder, pancreas	25	8.7	NS^*
Renal involvement^**	54.5	43.8	NS^*
Proteinuria	40.9	29.4	NS^*
Eosinophils in urine	36.4	35.3	NS^*
Nephritis or nephrosis	9.1	11.8	NS^*
Skin involvement	66.7	61.9	NS^*
Arthritis	31.8	37.5	NS^*
Myalgia	17.6	20.8	NS^*
Central nervous system involvement	13.6	25	NS^*
Extravascular eosinophils (pathology)	90.9	83.3	NS^*
ACR 4 of the 6,5 of the 6,6 of the 6	1/6/15	3/8/13	NS^*
Cumulative organ involvement^***, n, mean ± SD	5.2 ± 1.9	4.5 ± 1.7	NS^†
5-factor score	2.1 ± 0.9	1.4 ± 0.8	p < 0.01^†

Values of p < 0.05 considered statistically significant.
↵† 2-way ANOVA with repeated measures among 2 groups.
↵* Chi-square testing revealed no significant differences in frequencies of the 2 groups.
↵** Renal involvement including proteinuria, eosinophils in urine, glomerular nephritis, nephrosis, or renal dysfunction.
↵*** Cumulative organ involvement excluding asthma and sinusitis. EGPA: eosinophilic granulomatosis with polyangiitis; IVIG: intravenous immunoglobulin; NS: not significant; MMT: manual muscle test; ACR: American College of Rheumatology.